Parkside Financial Bank & Trust trimmed its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 3.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 15,812 shares of the company’s stock after selling 575 shares during the quarter. Johnson & Johnson makes up 0.7% of Parkside Financial Bank & Trust’s holdings, making the stock its 27th largest position. Parkside Financial Bank & Trust’s holdings in Johnson & Johnson were worth $2,451,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. US Financial Advisors LLC lifted its stake in Johnson & Johnson by 5.0% in the 1st quarter. US Financial Advisors LLC now owns 3,637 shares of the company’s stock valued at $564,000 after purchasing an additional 174 shares during the last quarter. Strengthening Families & Communities LLC grew its holdings in Johnson & Johnson by 6.0% in the first quarter. Strengthening Families & Communities LLC now owns 12,538 shares of the company’s stock worth $89,586,000 after purchasing an additional 707 shares during the period. Summit Trail Advisors LLC grew its holdings in Johnson & Johnson by 4.9% in the first quarter. Summit Trail Advisors LLC now owns 12,266 shares of the company’s stock worth $1,901,000 after purchasing an additional 578 shares during the period. Journey Advisory Group LLC grew its holdings in shares of Johnson & Johnson by 3.4% during the first quarter. Journey Advisory Group LLC now owns 59,959 shares of the company’s stock valued at $9,294,000 after buying an additional 1,990 shares during the last quarter. Finally, Cook Wealth Management Group LLC grew its holdings in shares of Johnson & Johnson by 1.6% during the first quarter. Cook Wealth Management Group LLC now owns 8,179 shares of the company’s stock valued at $1,333,000 after buying an additional 127 shares during the last quarter. 67.57% of the stock is owned by institutional investors.
Johnson & Johnson Trading Up 2.4 %
Johnson & Johnson stock opened at $173.10 on Tuesday. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04. The firm has a market cap of $449.88 billion, a PE ratio of 35.04, a P/E/G ratio of 2.84 and a beta of 0.54. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock’s 50 day simple moving average is $163.10 and its two-hundred day simple moving average is $160.99.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is 96.36%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the completion of the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Insiders sold a total of 47,163 shares of company stock valued at $7,928,856 in the last three months. 0.20% of the stock is owned by corporate insiders.
Analyst Ratings Changes
JNJ has been the topic of several research reports. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Barclays boosted their price target on shares of Johnson & Johnson from $171.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Monday, July 24th. Raymond James upped their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the company an “outperform” rating in a research note on Monday, July 24th. Morgan Stanley reiterated an “equal weight” rating and set a $187.00 price target on shares of Johnson & Johnson in a report on Friday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday, July 31st. Eight equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $171.80.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- Most Volatile Stocks, What Investors Need to Know
- 8 Best Meme Stocks to Buy Now
- Mega Cap Stocks: What They Are and How to Invest
- Is Now The Time To Buy XLF Financial ETF?
- How Technical Indicators Can Help You Find Oversold Stocks
- Three Ways To Play The Rise In Oil Prices
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
